Novo Nordisk consensus after Morningstar downgrade, shares remain in focus on NYSE and Copenhagen
25.06.2026 - 20:55:31 | ad-hoc-news.de
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-25, 20:54.
Novo Nordisk (DK0060534915) sits at the center of a clear but divided analyst consensus after a fresh Morningstar downgrade to Hold with a reiterated target of 343 Danish kroner, while the stock continues to trade actively on Nasdaq Copenhagen and as an ADR on the NYSE. MarketScreener lists the Morningstar action and latest Copenhagen prices.
What Morningstar changed this week
On June 25, MarketScreener reported that Morningstar cut Novo Nordisk from Buy to Hold and at the same time reiterated a target price of 343 Danish kroner, citing valuation concerns after the strong rally in GLP-1 obesity and diabetes franchises. The Morningstar downgrade summary on MarketScreener outlines the rating move.
According to the same overview, Novo Nordisk B shares on Nasdaq Copenhagen most recently traded around DKK 315 with an intraday gain of just over 1 percent and volume above 1.6 million shares, underscoring the continued liquidity in the blue-chip name. Live quote data from MarketScreener shows price and volume for the Copenhagen listing.
How other houses value the stock
The Morningstar move comes on top of existing divergent views at major banks: Deutsche Bank has a Hold rating with a 290 kroner target, while Berenberg recently set a Buy with a 325 kroner target, according to German analysis flashes cited by BörsenNews on the newer DK0062498333 line that references Novo Nordisk. BörsenNews summarizes the Deutsche Bank and Berenberg target levels.
MarketScreener’s consensus page groups several broker opinions and shows Novo Nordisk covered by large international houses such as Nordea, Deutsche Bank and Oddo BHF, with a mix of Buy and Hold stances reflecting both strong earnings momentum and valuation caution in the S&P 500-linked ADR and in Copenhagen trading. The consensus tab on MarketScreener aggregates broker ratings and targets.
All news and analysis on the Novo Nordisk shares
Further background on analyst views, price data and regulatory filings for Novo Nordisk can be found in the dedicated topic section and on the company’s investor relations pages.
The products behind the valuation debate
Novo Nordisk generates most of its revenue from diabetes and obesity treatments, with blockbuster GLP-1 products Ozempic (for type 2 diabetes) and Wegovy (for obesity) at the center of growth, alongside long-established insulin brands and newer injectable therapies.
Where the shares trade today
The Novo Nordisk B shares (DK0060534915) most recently changed hands on Nasdaq Copenhagen at around 315.10 Danish kroner on 2026-06-25, while the NYSE-listed ADR NVO quoted near 47.55 US dollars intraday, both according to recent MarketScreener and MarketBeat data.
Key data on the Novo Nordisk shares
- Company: Novo Nordisk A/S
- ISIN: DK0060534915
- WKN: A1XA8R
- Ticker: NOVO-B (Copenhagen), NVO (NYSE ADR)
- Trading venue: Nasdaq Copenhagen, NYSE (ADR)
- Price (as of 2026-06-25, 16:00): 315.10 DKK (Copenhagen), 47.55 USD (NYSE ADR)
- Market cap: approximately 2,150 billion DKK (as of 2026-06-25)
- Sector / industry: Health Care / Pharmaceuticals & Biotechnology
- Index membership: OMX Copenhagen 25, Euro Stoxx 50, S&P 500 (via ADR inclusion in several indices)
- Next earnings date: 2026-08-07
This article is for informational purposes only and does not constitute investment advice, an offer, or a solicitation to buy or sell any financial instrument. All data are based on sources believed to be reliable but cannot be guaranteed. Investors should conduct their own research or consult a qualified financial advisor before making investment decisions.
